【News】Capital and business alliance with Kamui Pharma, Inc., a drug discovery startup focused on probiotic medicine
CYBERDYNE Inc. (Tsukuba, Ibaraki, Japan; President & CEO: Yoshiyuki Sankai; from now on referred to as the “Company”) and Kamui Pharma, Inc. (Asahikawa, Hokkaido, Japan; President & CEO: Naoki Ogawa; from now on referred to as “Kamui Pharma”), a spin-off drug discovery startup from Asahikawa Medical University focused on probiotic medicine, announced to form a capital and business alliance (CYBERDYNE’s investment in Kamui Pharma). Furthermore, the Cybernics Excellence Japan Fund 1 Investment Limited Partnership (CEJ Fund), operated by the Company’s subsidiary, will also invest in Kamui Pharma.
Using microorganisms, also known as probiotics, Kamui Pharma promotes research and development of polyphosphate preparations for inflammatory bowel disease and ferrichrome for pancreatic cancer. Probiotics are gathering interest as a valuable substance for the human body. Probiotics have coexisted in the human body for a long history. Even a group of people with weak resistance to some type of medications, such as the elderly, can safely ingest probiotics for an extended period.
Through this alliance, the Company will support Kamui Pharma’s drug discovery business and coordinate closely to develop new non-pharmaceutical products utilizing probiotics, thereby promoting the realization of a “healthy future society” that enables social participation while maintaining a high level of independence and health, and a “Society 5.0/5.1
■ Kamui Pharma, Inc. Press Release (only Japanese available): https://www.kamuipharma.co.jp/news